{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:05:41Z","timestamp":1777039541430,"version":"3.51.4"},"reference-count":25,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1136\/bjophthalmol-2015-307299","type":"journal-article","created":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T03:58:43Z","timestamp":1452571123000},"page":"1341-1345","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":41,"title":["Changing from a<i>pro re nata<\/i>treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration"],"prefix":"10.1136","volume":"100","author":[{"given":"Katja","family":"Hatz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Pr\u00fcnte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,1,11]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2015-307299-1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bjo.2009.159160","article-title":"Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials","volume":"94","author":"Mitchell","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-307299-2","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/bjophthalmol-2015-307299-3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/bjophthalmol-2015-307299-4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajo.2010.04.011","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2","volume":"150","author":"Abraham","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-307299-5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307299-6","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307299-7","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307299-8","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1097\/IAE.0000000000000134","article-title":"Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years","volume":"34","author":"Abedi","year":"2014","journal-title":"Retina (Philadelphia, PA)"},{"key":"key-10.1136\/bjophthalmol-2015-307299-9","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","article-title":"A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact","volume":"117","author":"Gupta","year":"2010","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307299-10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/IAE.0b013e3181de5609","article-title":"Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration","volume":"31","author":"Oubraham","year":"2011","journal-title":"Retina (Philadelphia, PA)"},{"key":"key-10.1136\/bjophthalmol-2015-307299-11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/IAE.0b013e3182831265","article-title":"A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration","volume":"33","author":"Toalster","year":"2013","journal-title":"Retina (Philadelphia, PA)"},{"key":"key-10.1136\/bjophthalmol-2015-307299-12","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/IAE.0b013e3181bfbd46","article-title":"\u201cTreat and extend\u201d dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization\/retinal angiomatous proliferation","volume":"29","author":"Engelbert","year":"2009","journal-title":"Retina (Philadelphia, PA)"},{"key":"key-10.1136\/bjophthalmol-2015-307299-13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ajo.2007.02.024","article-title":"Ranibizumab according to need: a treatment for age-related macular degeneration","volume":"143","author":"Spaide","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-307299-14","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/IAE.0b013e3181d50cbf","article-title":"Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified \u201ctreat and extend\u201d dosing regimen of intravitreal antivascular endothelial growth factor therapy","volume":"30","author":"Engelbert","year":"2010","journal-title":"Retina (Philadelphia, PA)"},{"key":"key-10.1136\/bjophthalmol-2015-307299-15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307299-16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2014.09.033","article-title":"Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema","volume":"159","author":"Rayess","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-307299-17","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","article-title":"A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration","volume":"116","author":"Boyer","year":"2009","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307299-18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","article-title":"Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study","volume":"118","author":"Holz","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307299-19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-307299-20","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307299-21","unstructured":"Novartis Pharma AG. Lucentis\u00ae: summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/ema"},{"key":"key-10.1136\/bjophthalmol-2015-307299-22","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1097\/IAE.0000000000000182","article-title":"Retina specialists treating age-related macular degeneration recommend different approaches for patients than they would choose for themselves","volume":"34","author":"Jeng","year":"2014","journal-title":"Retina (Philadelphia, PA)"},{"key":"key-10.1136\/bjophthalmol-2015-307299-23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcjo.2014.03.009","article-title":"Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada","volume":"49","author":"Xing","year":"2014","journal-title":"Can J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-307299-24","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307299-25","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00417-012-2177-3","article-title":"Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life","volume":"251","author":"Droege","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2015-307299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:51:18Z","timestamp":1601110278000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2015-307299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,11]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,9,22]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1136\/bjophthalmol-2015-307299"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307299","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,11]]}}}